GET DAILY SIGNALSOvid Therapeutics (OVID): A Focused Look at Its Pipeline in Neurological Disorders
Key Takeaways
- Ovid Therapeutics (OVID) is a clinical-stage biopharmaceutical company focused on developing small molecule medicines for brain and neurological disorders.
- The company's lead programs target drug-resistant epilepsies and other seizure-related conditions, including OV329 and OV4071.
- Ovid was founded in 2014, is headquartered in New York, and has been publicly traded on the Nasdaq since May 2017.
- As a development-stage company, Ovid generates limited revenue and has historically reported net losses, relying on capital raises and collaborations to fund research.
- The company's value proposition rests on its pipeline and intellectual property rather than on commercial product sales.
Introduction
From what I see, Ovid Therapeutics (OVID) stands out as a New York-based biopharmaceutical company dedicated to discovering and developing differentiated, small molecule medicines for neurological and neuropsychiatric conditions with significant unmet medical need. Unlike large pharmaceutical companies with many marketed products, Ovid operates as a clinical-stage developer: its primary focus is advancing drug candidates through research and clinical trials, particularly for rare epilepsies and seizure-related disorders. Investors follow OVID for its emerging pipeline and the potential of its novel drug mechanisms rather than for current revenue or earnings. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Company Background and History
Ovid Therapeutics was founded in April 2014 by Dr. Matthew During, an accomplished neuroscientist, and Dr. Jeremy Levin, a physician and former CEO of Teva Pharmaceuticals. The company was established with the goal of tackling rare neurological conditions that larger pharmaceutical companies had often overlooked or under-served. The name "Ovid" was inspired by the Roman poet and his work The Metamorphoses, reflecting the founders' ambition to bring about meaningful change in the treatment of brain disorders.
Ovid is incorporated in Delaware and maintains its principal executive office in New York, New York. The company completed its initial public offering (IPO) in May 2017 and its shares trade on the Nasdaq exchange under the ticker symbol OVID. As a relatively small organization, Ovid employs a focused team of roughly two dozen people, consistent with its lean, research-driven business model.
Business Model and Pipeline
Ovid's business model centers on drug discovery and clinical development rather than manufacturing or large-scale commercialization. The company uses small molecule medicines—drugs with low molecular weight that can typically be administered orally and reach targets inside the body—to modulate neural activity. Its research focuses on conditions driven by excess neural excitability, which can cause seizures and other neurological symptoms. One thing that stands out is how the company leverages partnerships to support its work.
Ovid's two most prominent clinical programs are:
- OV329, a next-generation GABA-aminotransferase (GABA-AT) inhibitor being developed as a potential treatment for treatment-resistant seizures and related disorders. GABA-AT inhibitors target a mechanism of action that has been validated in multiple seizure conditions.
- OV4071, an oral potassium-chloride cotransporter 2 (KCC2) direct activator, being investigated for psychosis associated with Parkinson's disease, Lewy body dementia, and acute schizophrenia, as well as other central nervous system disorders.
Because these candidates are still in clinical development, Ovid's primary revenue sources are limited and have historically come from licensing, collaboration, and royalty arrangements. The company has entered into license and collaboration agreements with partners including AstraZeneca, H. Lundbeck A/S, Northwestern University, Graviton, and Marinus Pharmaceuticals, Inc. These partnerships can provide milestone payments and royalties if programs advance successfully.
Market Position and Competitive Landscape
Ovid operates within the competitive biotechnology and neurology space, where it competes with both large pharmaceutical companies and other clinical-stage biotechs developing therapies for epilepsy and neuropsychiatric disorders. The company differentiates itself through its focus on potential first-in-class or best-in-class mechanisms of action, aiming to address seizure disorders that remain poorly controlled by existing anti-seizure medications. According to Ovid, nearly 50 million people worldwide live with epilepsies and seizures, and a substantial portion continue to experience seizures despite taking multiple medications, underscoring the unmet need the company seeks to address. I’m watching this closely as the space evolves.
Why Investors Follow OVID
Investor interest in OVID is tied primarily to its pipeline potential and its financial profile as an early-stage biotechnology company. Key drivers of attention include the advancement of OV329 and OV4071 through clinical trials, the possibility of regulatory milestones or partnerships, and the company's intellectual property portfolio. For investors in development-stage biotech, clinical data readouts and partnership activity often represent the most significant catalysts, since a single successful program can materially change a company's outlook.
Risks and Important Considerations
Investing in Ovid Therapeutics carries risks common to clinical-stage biotechnology companies. These include the inherent uncertainty of clinical trial outcomes, potential regulatory hurdles, and the long timelines required to bring a drug to market. Ovid has historically reported recurring net losses and negative operating cash flow, and its financial profile depends on raising additional capital through equity offerings, debt, or partnerships. There is no guarantee that its drug candidates will receive regulatory approval or generate meaningful revenue. Competition in neurology is intense, and technological or scientific setbacks could affect the value of its pipeline. Prospective investors should carefully consider these factors in light of their own risk tolerance.
Integrating AI Tools Into Biotech Research
In my view, Tickeron’s AI Screener has become a useful part of how I review opportunities in the biotech sector. It helps surface ideas based on technical indicators, fundamentals, volatility, trends, and customizable filters, which can be particularly relevant when evaluating names like OVID alongside peers. I find it streamlines the process of comparing clinical-stage companies without replacing deeper fundamental analysis.
Conclusion
Ovid Therapeutics is a focused, clinical-stage biopharmaceutical company working to develop novel small molecule treatments for epilepsy and other serious brain disorders. Its identity as an early-stage developer means its value is closely tied to the progress of its research pipeline rather than to current sales or profits. For investors interested in the neuroscience and rare-disease segments of biotechnology, OVID represents a company whose market position and future trajectory will depend heavily on the outcomes of its clinical programs and its ability to secure the capital and partnerships needed to advance them.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OVID's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for OVID turned positive on October 21, 2026. Looking at past instances where OVID's MACD turned positive, the stock continued to rise in 48 of 52 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OVID's RSI Indicator exited the oversold zone, 17 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on OVID as a result. In 76 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
OVID moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for OVID crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +14.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in 207 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
OVID broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for OVID entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.652) is normal, around the industry mean (3.498). P/E Ratio (-13.571) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (204.082) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Provides medicines to children and adults with neurological disorders
Industry Biotechnology
Advertisement